Status:
UNKNOWN
Utility of Lactoferrin as an Adjunct Therapeutic Agent for COVID-19
Lead Sponsor:
Cairo University
Conditions:
COVID-19
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
PHASE3
Brief Summary
There is currently no clinically proven specific antiviral agent available for SARS-CoV-2 infection. Supportive treatment, including oxygen therapy, remains the most important management strategy. Si...
Detailed Description
COVID-19 has a wide clinical spectrum ranging between asymptomatic infection, mild upper respiratory tract symptoms, and severe viral pneumonia that may result in respiratory failure and finally death...
Eligibility Criteria
Inclusion
- Positive reverse-transcriptase-polymerase chain- reaction (RT-PCR) assay for SARS- CoV-2 in a respiratory tract sample.
Exclusion
- Known allergy or hypersensitivity to the used medications
- Severe symptoms: respiratory insufficiency that requires admission in intensive care unit or mechanical ventilation
Key Trial Info
Start Date :
June 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2020
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT04421534
Start Date
June 1 2020
End Date
November 1 2020
Last Update
June 9 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.